Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Patel Gautam, a director at Amneal Pharmaceuticals, Inc. (NYSE:NASDAQ:AMRX), recently sold 80,000 shares of the company’s Class A Common Stock. The shares were sold at a weighted average price of $8.90 per share, totaling approximately $712,000. The transaction comes as AMRX trades near its 52-week high of $9.47, having delivered an impressive 69% return over the past year. According to InvestingPro analysis, the stock is currently fairly valued, with analysts setting price targets between $11-12. This transaction was executed on March 3, 2025, as part of a pre-established trading plan under Rule 10b5-1(c), which allows company insiders to set up a predetermined plan to sell stocks. Following this sale, Patel retains ownership of 1,808,886 shares in Amneal Pharmaceuticals, representing a significant stake in the $2.79 billion market cap company. While currently unprofitable, analysts expect Amneal to turn profitable this year, with multiple upward earnings revisions for the upcoming period.
In other recent news, Amneal Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing a slight miss on earnings per share (EPS) expectations, with an EPS of $0.12 compared to the anticipated $0.15. However, the company exceeded revenue forecasts, achieving $731 million against the expected $703.74 million. This revenue performance marks an 18% year-over-year increase for the quarter, contributing to a total annual revenue of $2.8 billion, a 17% rise from the previous year. Amneal has also launched a new Parkinson’s drug, Krexant, which has shown promising sales targets and is expected to contribute significantly to its specialty segment growth.
Additionally, Amneal Pharmaceuticals, in collaboration with mAbxience, announced that the FDA has accepted their Biologics Licensing Application for two biosimilars of denosumab, with a target action date set for the fourth quarter of 2025. These biosimilars could potentially provide more affordable alternatives to existing treatments for bone-related conditions. The company’s strategic focus on expanding its biosimilars portfolio aligns with its long-term growth objectives in the U.S. market.
Furthermore, Amneal has received credit upgrades from S&P and Moody’s, reflecting its improved financial profile and reduced net leverage to 3.9 times from 4.8 times in the previous year. The company aims to further decrease its net leverage below 3 times in the coming years. Looking ahead, Amneal has set a revenue guidance range of $3.0 to $3.1 billion for 2025, indicating a projected growth rate of 7-11%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.